Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line Metastatic Nonsquamous Non-Small-Cell Lung Cancer
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs pembrolizumab plus maintenance pemetrexed for the treatment of nonsquamous NSCLC. The study’s 2 primary hypotheses are: 1. Pembrolizumab plus maintenance